APA citiranje

Preiss, D., Herrington, W., & Haynes, R. (2022). Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: The EMPA-KIDNEY trial. American Heart Association.

Chicago Style (17th ed.) Citation

Preiss, D., W. Herrington, and R. Haynes. Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial. American Heart Association, 2022.

MLA citiranje

Preiss, D., et al. Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial. American Heart Association, 2022.